Clinical trials
Bipolar Disorder I or II clinical trials
Below are recruiting bipolar disorder i or ii clinical trials, each written for real people, not researchers. We’re tracking 2,351 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06577779RecruitingPhase 4
Testing Jornay PM for adult ADHD symptoms into the evening
This study tests if Jornay PM, a long-acting ADHD medication, helps control symptoms, focus, and emotions throughout the day and into the early evening in adults with ADHD. It is an open-label study, meaning everyone knows they are getting the medication, and then they are randomly assigned to different observation groups.
New York, New YorkAges 18–60 - NCT06567210Recruiting
Insomnia treatment and emotional memory regulation for mental health
This study tests whether treating insomnia can help regulate emotional memories overnight, which may reduce the risk of developing or worsening mental health conditions. You may be eligible if you have both insomnia and some anxiety symptoms.
Macquarie Park, New South WalesAges 18–45 - NCT06575751RecruitingPhase 2
Study of cannabidiol and cannabis concentrate users
This study looks at how cannabidiol (a compound in cannabis) affects people who regularly use strong cannabis concentrates like wax, shatter, or oil. It may help understand if using CBD can change how cannabis affects the body or help with cannabis use disorder.
Aurora, ColoradoAges 25–60 - NCT06569394RecruitingPhase 2
Testing CBD in young adults who use cannabis heavily
This study tests whether cannabidiol (CBD) can help young adults who use cannabis heavily but aren't looking to quit. You'll take a CBD pill and see if it changes your cannabis use or related symptoms.
Aurora, ColoradoAges 18–25 - NCT06582615Recruiting
MIND diet for better brain health during breast cancer treatment
This study tests whether a special diet (called the MIND diet) can help with thinking and memory in women being treated for triple negative breast cancer. Participants will receive nutrition coaching and support to see if it improves brain function.
New Haven, ConnecticutAges 40–65 - NCT06490536RecruitingPhase 3
Testing a new treatment for high-risk colon cancer after surgery
This trial tests a new treatment approach for people with certain high-risk colon cancers (stage II or III in the upper colon) after surgery. It aims to see if adding a study drug can help prevent the cancer from coming back.
BerlinAges 18 years+ - NCT06556693Recruiting
Study of a new device for severe sleep apnea
This study tests if a new device can help people with severe sleep-disordered breathing (like sleep apnea). It may be an option if you have no or well-managed heart failure and are able to follow study procedures.
Scottsdale, ArizonaAges 22 years+ - NCT06559150RecruitingPhase 2
Study of ensifentrine for non-cystic fibrosis bronchiectasis
This trial tests an inhaled drug called ensifentrine in people with bronchiectasis (damaged, widened airways in the lungs). The goal is to see if it can reduce flare-ups and improve symptoms.
Birmingham, AlabamaAges 18–80 - NCT06561087RecruitingPhase 2
Nivolumab injection for high-risk mouth lesions
This trial tests whether injecting nivolumab directly into high-risk pre-cancerous mouth spots can prevent them from becoming cancer. You randomly receive either the drug or a placebo, and the study monitors how the spots change over time.
Houston, TexasAges 18 years+ - NCT06552234RecruitingPhase 2
Study of repotrectinib for older or frail patients with ROS1-positive lung cancer
This trial tests an oral targeted therapy called repotrectinib in people with advanced non-small cell lung cancer (NSCLC) that has a change in the ROS1 gene. It is designed for patients who are either 70 or older, or have a lower performance status (ECOG 2 or higher), meaning they may be more frail or have more symptoms. The goal is to see if repotrectinib can help shrink or control the cancer.
Aix-en-Provence, Bouches Du RhôneAges 18 years+ - NCT06558604RecruitingPhase 2
Study of glofitamab with venetoclax for high-risk mantle cell lymphoma
This trial tests a new combination of drugs (glofitamab plus venetoclax, with or without zanubrutinib) for people with mantle cell lymphoma that is either newly diagnosed with high risk features, or has come back or not responded to earlier treatments. The goal is to see if these targeted therapies can improve outcomes.
BrugesAges 18–79 - NCT06553885RecruitingPhase 2
Study of enfortumab vedotin for advanced colorectal or liver cancer
This trial tests a drug called enfortumab vedotin for people whose colorectal or liver cancer has spread or cannot be removed and has stopped responding to or is intolerant to standard treatments. The drug is given through a vein and works by targeting cancer cells.
Tampa, FloridaAges 18 years+ - NCT06565052Recruiting
Exercise and nutrition before rectal cancer surgery study
This trial tests whether a personalized exercise and nutrition program before rectal cancer surgery can help you recover faster and have fewer complications. If you are not very active right now, you may be able to join.
Boston, MassachusettsAges 18 years+ - NCT06514495Recruiting
Virtual vs. real-life therapy for agoraphobia
This study compares facing fears in virtual reality versus real-life situations for people with agoraphobia. Researchers want to see which method works better to reduce anxiety.
MainzAges 18–75 - NCT06540833RecruitingPhase 2
Study of a new drug for psychosis in people with Alzheimer's disease
This trial tests an experimental medication to reduce hallucinations and delusions in people who have Alzheimer's disease. It may help manage these symptoms and improve quality of life for patients and their caregivers.
Anaheim, CaliforniaAges 55 years+ - NCT06537921Recruiting
Testing minocycline for depression with obesity
This trial tests whether adding the antibiotic minocycline to your current antidepressant helps people with both depression and obesity. It aims to see if reducing inflammation can improve mood.
LondonAges 18–65 - NCT06534125Recruiting
Acupuncture to prevent joint pain from hormone therapy in Black women
This study tests whether acupuncture can prevent joint pain caused by a common hormone therapy pill (aromatase inhibitor) in Black women who have finished treatment for early-stage breast cancer.
Atlanta, GeorgiaAges 18 years+ - NCT06538246Recruiting
Coping skills training for heart and lung failure survivors
This study tests a coping skills training program to help people who recently survived a serious heart or lung problem feel less anxious, depressed, or stressed. If you were in the ICU and now feel distressed at home, you may be able to join.
Durham, North CarolinaAges 18 years+ - NCT06540326RecruitingPhase 2
Second-line therapy for advanced colorectal cancer
This trial tests a combination of chemotherapy with either bevacizumab or cetuximab as a second-line treatment for advanced colorectal cancer. It aims to find which option works better for patients whose first treatment failed.
Hangzhou, ZhejiangAges 18–75 - NCT06520098RecruitingPhase 2
BTK inhibitor with or without venetoclax for CLL/SLL
This trial tests whether adding venetoclax to your current BTK inhibitor (like ibrutinib, acalabrutinib, or zanubrutinib) works better than taking the BTK inhibitor alone. It's for veterans with CLL or SLL who have been on a BTK inhibitor for at least six months and have not had their disease get worse on that therapy.
San Francisco, CaliforniaAges 18–80 - NCT06523439Recruiting
Brain stimulation for depression in young people
This study tests a new type of brain stimulation called accelerated intermittent theta burst stimulation (aiTBS) in young people (ages 13-20) with depression who have not tried many treatments before. The goal is to see if this treatment can safely help reduce depression symptoms.
Austin, TexasAges 13–20 - NCT06526208RecruitingPhase 2
Marijuana-based compound for anxiety in autistic adults
This study tests a marijuana-based compound (similar to CBD but not psychoactive) to see if it helps reduce anxiety in autistic adults. You would take a daily capsule and be monitored for 12 weeks.
Phoenix, ArizonaAges 18–45 - NCT06528938Recruiting
Accelerated vs. standard TMS for teen depression
This study tests whether a faster, brain-guided form of TMS (called iTBS) can help treat depression in teenagers better than standard TMS. You may qualify if you're 16–19, have tried an antidepressant that didn't work well, and have no medical reasons to avoid TMS or MRI.
Ottawa, OntarioAges 16–19 - NCT06248593RecruitingPhase 4
Continuous Norepinephrine vs Phenylephrine for Cesarean Blood Pressure
This study compares two medicines (norepinephrine and phenylephrine) given continuously through a vein to keep your blood pressure stable during a planned cesarean with spinal anesthesia. It aims to see which medicine works better for you and your baby.
FesAges 18–45
Hear when a new Bipolar Disorder I or II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bipolar disorder i or ii?
- Yes. Clin2 currently lists 2,351 recruiting bipolar disorder i or ii studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bipolar disorder i or ii trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bipolar disorder i or ii trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.